FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162216424> ?p ?o ?g. }

• W2162216424 endingPage "405" @default.
• W2162216424 startingPage "399" @default.
• W2162216424 abstract "We conducted a pediatric phase I trial of the vascular endothelial growth factor (VEGF)-neutralizing antibody bevacizumab (BV). Primary aims included estimating the maximum-tolerated dose (MTD) and determining the dose-limiting toxicities (DLTs), pharmacokinetics, and biologic effects of BV in children with cancer.BV (5, 10, 15 mg/kg) was administered intravenously every 2 weeks in 28-day courses to children with refractory solid tumors.Twenty-one patients enrolled, 20 (median age, 13 years) were eligible, and 18 completed one course and were fully assessable for toxicity. A total of 67 courses were administered (median, three courses per patient; range, one to 16 courses). Treatment was well tolerated with no DLTs observed. Non-DLTs included infusional reaction, rash, mucositis, proteinuria, and lymphopenia. Increases in systolic and diastolic blood pressure not meeting Common Terminology Criteria for Adverse Events (CTCAEv3) pediatric-specific criteria for hypertension were observed. There was no hemorrhage or thrombosis. Growth perturbation was not detected in a limited sample over the first course. The serum exposure to BV as measured by area under the concentration-time curve (AUC) seemed to increase in proportion to dose. The median clearance of BV was 4.1 mL/d/kg (range, 3.1 to 15.5 mL/d/kg), and the median half-life was 11.8 days (range, 4.4 to 14.6 days). No objective responses were observed. Exploratory analyses on circulating endothelial mobilization and viability are consistent with the available adult data.BV is well tolerated in children. Phase II pediatric studies of BV in combination with chemotherapy in dosing schedules similar to adults are planned." @default.
• W2162216424 created "2016-06-24" @default.
• W2162216424 creator A5010799165 @default.
• W2162216424 creator A5012647498 @default.
• W2162216424 creator A5021851526 @default.
• W2162216424 creator A5027416118 @default.
• W2162216424 creator A5027468886 @default.
• W2162216424 creator A5031841410 @default.
• W2162216424 creator A5038794162 @default.
• W2162216424 creator A5045409088 @default.
• W2162216424 creator A5066484657 @default.
• W2162216424 creator A5068166516 @default.
• W2162216424 creator A5068839681 @default.
• W2162216424 creator A5073659294 @default.
• W2162216424 creator A5078860285 @default.
• W2162216424 creator A5080530418 @default.
• W2162216424 creator A5083758349 @default.
• W2162216424 creator A5090325707 @default.
• W2162216424 date "2008-01-20" @default.
• W2162216424 modified "2023-10-16" @default.
• W2162216424 title "Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study" @default.
• W2162216424 cites W110134706 @default.
• W2162216424 cites W1583699618 @default.
• W2162216424 cites W1968539943 @default.
• W2162216424 cites W1969328947 @default.
• W2162216424 cites W1976893749 @default.
• W2162216424 cites W2000292756 @default.
• W2162216424 cites W2038647733 @default.
• W2162216424 cites W2046507292 @default.
• W2162216424 cites W2047508936 @default.
• W2162216424 cites W2090401954 @default.
• W2162216424 cites W2092104690 @default.
• W2162216424 cites W2094794021 @default.
• W2162216424 cites W2108114500 @default.
• W2162216424 cites W2115280603 @default.
• W2162216424 cites W2117859020 @default.
• W2162216424 cites W2118266456 @default.
• W2162216424 cites W2131138603 @default.
• W2162216424 cites W2135179491 @default.
• W2162216424 cites W2139248078 @default.
• W2162216424 cites W2145224595 @default.
• W2162216424 cites W2145835533 @default.
• W2162216424 cites W2150709721 @default.
• W2162216424 cites W2154736427 @default.
• W2162216424 cites W2157769714 @default.
• W2162216424 cites W2163899134 @default.
• W2162216424 cites W2170655985 @default.
• W2162216424 cites W4239661414 @default.
• W2162216424 cites W74687677 @default.
• W2162216424 doi "https://doi.org/10.1200/jco.2007.11.9230" @default.
• W2162216424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18202416" @default.
• W2162216424 hasPublicationYear "2008" @default.
• W2162216424 type Work @default.
• W2162216424 sameAs 2162216424 @default.
• W2162216424 citedByCount "215" @default.
• W2162216424 countsByYear W21622164242012 @default.
• W2162216424 countsByYear W21622164242013 @default.
• W2162216424 countsByYear W21622164242014 @default.
• W2162216424 countsByYear W21622164242015 @default.
• W2162216424 countsByYear W21622164242016 @default.
• W2162216424 countsByYear W21622164242017 @default.
• W2162216424 countsByYear W21622164242018 @default.
• W2162216424 countsByYear W21622164242019 @default.
• W2162216424 countsByYear W21622164242020 @default.
• W2162216424 countsByYear W21622164242021 @default.
• W2162216424 countsByYear W21622164242022 @default.
• W2162216424 countsByYear W21622164242023 @default.
• W2162216424 crossrefType "journal-article" @default.
• W2162216424 hasAuthorship W2162216424A5010799165 @default.
• W2162216424 hasAuthorship W2162216424A5012647498 @default.
• W2162216424 hasAuthorship W2162216424A5021851526 @default.
• W2162216424 hasAuthorship W2162216424A5027416118 @default.
• W2162216424 hasAuthorship W2162216424A5027468886 @default.
• W2162216424 hasAuthorship W2162216424A5031841410 @default.
• W2162216424 hasAuthorship W2162216424A5038794162 @default.
• W2162216424 hasAuthorship W2162216424A5045409088 @default.
• W2162216424 hasAuthorship W2162216424A5066484657 @default.
• W2162216424 hasAuthorship W2162216424A5068166516 @default.
• W2162216424 hasAuthorship W2162216424A5068839681 @default.
• W2162216424 hasAuthorship W2162216424A5073659294 @default.
• W2162216424 hasAuthorship W2162216424A5078860285 @default.
• W2162216424 hasAuthorship W2162216424A5080530418 @default.
• W2162216424 hasAuthorship W2162216424A5083758349 @default.
• W2162216424 hasAuthorship W2162216424A5090325707 @default.
• W2162216424 hasBestOaLocation W21622164241 @default.
• W2162216424 hasConcept C112705442 @default.
• W2162216424 hasConcept C121332964 @default.
• W2162216424 hasConcept C126322002 @default.
• W2162216424 hasConcept C142424586 @default.
• W2162216424 hasConcept C197934379 @default.
• W2162216424 hasConcept C2776694085 @default.
• W2162216424 hasConcept C2777793932 @default.
• W2162216424 hasConcept C2777802072 @default.
• W2162216424 hasConcept C2778496288 @default.
• W2162216424 hasConcept C2778570526 @default.
• W2162216424 hasConcept C2779561371 @default.
• W2162216424 hasConcept C2780091579 @default.
• W2162216424 hasConcept C29730261 @default.

• next